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Abstract
RUNX2 and SP7 are essential transcription factors for osteoblast differentiation at an early stage. Although RUNX2 inhibits
osteoblast differentiation at a late stage, the function of SP7 at the late stage of osteoblast differentiation is not fully
elucidated. Thus, we pursued the function of SP7 in osteoblast differentiation. RUNX2 induced Sp7 expression in Runx2
2/2
calvarial cells. Adenoviral transfer of sh-Sp7 into primary osteoblasts reduced the expression of Alpl, Col1a1,a n dBglap2 and
mineralization, whereas that of Sp7 reduced Bglap2 expression and mineralization at a late stage of osteoblast differentiation.
Sp7 transgenic mice under the control of 2.3 kb Col1a1 promoter showed osteopenia and woven-bone like structure in the
cortical bone, which was thin and less mineralized, in a dose-dependent manner. Further, the number of processes in the
osteoblastsandosteocyteswasreduced.Althoughtheosteoblastdensitywasincreased,theboneformationwasreduced.The
frequency of BrdU incorporation was increased in the osteoblastic cells, while the expression of Col1a1, Spp1, Ibsp,a n dBglap2
was reduced. Further, the osteopenia in Sp7 or Runx2 transgenic mice was worsened in Sp7/Runx2 double transgenic mice and
the expression of Col1a1 and Bglap2 was reduced. The expression of Sp7 and Runx2 was not increased in Runx2 and Sp7
transgenic mice, respectively. The expression of endogenous Sp7 was increased in Sp7 transgenic mice and Sp7-transduced
cells; the introduction of Sp7 activated and sh-Sp7 inhibited Sp7 promoter; and ChIP assay showed the binding of endogenous
SP7 in the proximal region of Sp7 promoter. These findings suggest that SP7 and RUNX2 inhibit osteoblast differentiation at a
late stage in a manner independent of RUNX2 and SP7, respectively, and SP7 positively regulates its own promoter.
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Introduction
After multipotent mesenchymal cells commit to the osteoblastic
lineage, preosteoblasts differentiate into osteoblasts, which express
bone matrix proteins including COL1A1, COL1A2, SPP1 (osteo-
pontin), IBSP (bone sialoprotein), and BGLAP2 (osteocalcin) [1].
RUNX2, SP7/Osterix,and canonicalWnt signaling areessentialfor
the commitment of mesenchymal cells to the osteoblastic lineage [2],
[3]. The osteoblasts then express bone matrix protein genes at
different levels depending on the maturity of the cells. Mesenchymal
cells and preosteoblasts weakly express Col1a1 and Col1a2,b u t
osteoblasts showed increased levels. Immature osteoblasts express
Spp1 and then Ibsp, and mature osteoblasts strongly express Bglap2
[1]. Mature osteoblasts are embedded into the bone matrix and
become osteocytes. Osteocytes, the most abundant cells in mature
bone, are extensively interconnected with other osteocytes and
osteoblasts through processes [4].
SP7 is a zinc finger-containing protein which belongs to the Sp/
KLF (Kruppel like Factor) family of transcription factors [5]. Sp7-
deficient (Sp7
2/2) mice are unable to form bone due to an arrest of
osteoblast differentiation. Their mesenchymal cells condense in the
perichondrial region, where bone normally forms, and express
Runx2 and genes for chondrocyte markers but not bone matrix
proteins. Therefore, SP7 is essential for osteoblast differentiation,
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2 mesenchymal cells (preosteoblasts) retain the
ability to differentiate into chondrocytes [5]. Further, osteoblast-
specific deletion of Sp7 resulted in osteopenia due to the inhibition
of osteoblast differentiation in adult mice [6]. However, the
function of SP7 after the commitment to the osteoblastic lineage is
not fully elucidated.
To pursue this issue, we over-expressed or silenced Sp7.
Introduction of sh-Sp7 inhibited osteoblast differentiation from the
early stage of osteoblast differentiation, but introduction of Sp7
inhibited osteoblast differentiation at a late stage in vitro.
Osteoblast-specific Sp7 transgenic mice showed osteopenia due to
the inhibition of osteoblast differentiation at a late stage, and SP7
positively regulated its own promoter. These findings suggest that
theregulationof Sp7 expressiondependingonthestage of osteoblast
differentiation isimportant forbone developmentand maintenance.
Materials and Methods
Ethics statement
Prior to the study, all experiments were reviewed and approved by
the Animal Care and Use Committee of NagasakiUniversity Graduate
School of Biomedical Sciences, permit number (0906170767-5).
Cell culture experiments
Calvaria from Runx2
2/2 and wild-type embryos at E18.5 were
embedded in a type I collagen gel matrix for 10 days and the cells
outspreading from the explants were collected using 0.1%
collagenase. The cells were then plated on 24-well plates at a
density of 5610
4/well. At confluence, they were infected with an
adenovirus expressing EGFP, Runx2,o rSp7. In vitro silencing of
Sp7 was obtained by adenoviral delivery of sh-RNA containing the
target sequence of ACAAAGAAGCCATACGCT. Primary oste-
oblasts were isolated from calvaria of wild-type mice at E18.5 by
sequential digestion with 0.1% collagenase A and 0.2% dispase.
Osteoblastic cells from the second to fifth fraction were pooled,
and plated on 24-well plates at a density of 5610
4/well. At
confluence, the osteoblastic cells were infected with an adenovirus
expressing EGFP, Sp7, sh-Sp7,o rRunx2. Cell viability evaluation
and retrovirus infection in primary osteoblasts were performed as
described in the Supporting Information files (Procedures S1 and
S2). To induce osteogenic differentiation the cells were cultured in
alfa-MEM (Sigma) containing 10%FBS (JRH), 10 mM b-glycero-
phosphate, and 50 mg/ml ascorbic acid. The staining for
mineralization was performed 10 days after the infection as
described previously [7].
Generation of Sp7 transgenic mice and Runx2/Sp7 double
transgenic mice
To generate transgenic mice that overexpress Sp7 in osteoblasts,
Sp7 cDNA was inserted into the mammalian expression vector
pNASSb (CLONTECH Laboratories Inc., Otsu, Japan) by
replacing the b-galactosidase gene at the Not I sites, and the
2.3-kb osteoblast-specific promoter region of mouse Col1a1 [8] was
inserted into the pNASSb at the XhoI site. To generate Runx2/Sp7
double transgenic mice, tg2 mice were mated with transgenic mice
that overexpress Runx2 under the control of the 2.3-kb mouse
Col1a1 promoter [9]. The urinary excretion of deoxypyridinoline
was measured using an ELISA kit (Metra Biosystems). Results
were expressed as deoxypyridinoline/creatinine (nmol/mmolCr).
Histological analyses
For histological analyses, mice were fixed in 4% paraformalde-
hyde/0.1 M phosphate buffer, and the long bones were decalcified
in 0.5 M EDTA/10% glycerol buffer (pH7.5) and embedded in
paraffin. Sections (7 mm thick) were stained with hematoxylin and
eosin (H–E) or subjected to immunohistochemistry using anti-SP7
antibody [10], Bone canalicular staining (silver impregnation
staining) was performed according to the method previously
described [11]. For bone histomorphometric analyses, the mice
received two injections of calcein at 6 days and 2 days before
sacrifice, and longitudinal sections from the distal parts of femurs
were analyzed as reported [12]. The BrdU incorporation
experiment was performed as detailed previously [13].
Real-time RT-PCR
Muscle, connective tissue, and periosteum were removed from
femurs and tibiae, and the bones were cut at the metaphyses. After
hematopoietic cells in the diaphyses of femurs and tibiae were
flushed out with PBS, osteoblasts were removed using a micro-
intertooth brush (Kobayashi Pharmaceutical Co. Ltd., Osaka,
Japan). The remaining bone was used as a source of osteocyte-
enriched cells. Nearly complete removal of osteoblasts from the
endosteum by the micro-intertooth brush was confirmed using a
scanning electron microscope (Miniscope TM-1000; Hitachi).
Real-time RT-PCR was performed as described previously [13]
using the following primers: transgene, 59-CCAGAAAGTTA-
ACTGGCCTGT-39/59-ATTCCGCAGCTTTTAGAGCAG-39;
Col1a1,5 9-CCCAAGGAAAAGAAGCACGTC-39/59-ACATTA-
GGCGCAGGAAGGTCA-39; Alpl,5 9-CGCACGCGATGCAA-
CACCAC-39/59- TGCCCACGGACTTCCCAGCA 39-; Spp1,
59-CTCCAATCGTCCCTACAGTCG-39/59-CCAAGCTATCA-
CCTCGGCC-39; Ibsp,5 9-TGGCGACACTTACCGAGCTT-39/
59-CCATGCCCCTTGTAGTAGCTGTA-39; Bglap2,5 9-CCTA-
GCAGACACCATGAG-39/59-TCTGATAGCTCGTCACAAG-
39; endogenous Sp7,5 9- CATCTGCCTGACTCCTTGGGAC-
39/59-GCTGAAAGGTCAGCGTATGGC-39; Sp7 (endogenous
and exogenous Sp7), 59-AGGCACAAAGAAGCCATAC-39/59-
AATGAGTGAGGGAAGGGT-39; Runx2 (endogenous and ex-
ogenous Runx2), 59-CTTCGTCAGCATCCTATCAGTTC-39/
59-TCAGCGTCAACACCATCATTC-39; Dmp1,5 9-GGCTGT-
CCTGTGCTCTCCCAG-39/59-GGTCACTATTTGCCTGTG-
CCTC-39; Sost,5 9-CTTCAGGAATGATGCCACAGAGGT-39/
59-ATCTTTGGCGTCATAGGGATGGTG-39; Fgf23,5 9-ACT-
TGTCGCAGAAGCATC-39/59-GTGGGCGAACAGTGTAG-
AA-39; Mepe,5 9-CAGTGGCTCCCCAGATCTTC-39/59-GCT-
TTCAGGACCAGACCCAG-39; Phex,5 9-GTGCATCTACC-
AACCAGATACG-39/59-TCTGTTCCCCAAAAGAAAGG-39;
Tnfsf11,5 9-CAAGCTCCGAGCTGGTGAAG-39/59-CCTGA-
ACTTTGAAAGCCCCA-39; Tnfrsf11b,5 9-AAGAGCAAACC-
TTCCAGCTGC-39/59-CACGCTGCTTTCACAGAGGTC-39;
Atf4,5 9-ACCTCATGGGTTCTCCAGC-39/59-CCATTCGAA-
ACAGAGCATCGA-39. CT (number of cycles at which the
threshold of detection was reached) values were normalized to that
for rodent Gapdh (Applied Biosystems) expression.
X-ray and pQCT analyses
Long bones were dissected from sacrificed mice at 6 weeks of
age and exposed to X-rays using a Micro-FX1000 (Fuji Film Inc.,
Tokyo, Japan). For the pQCT analysis, femurs from 10-week-old
mice were fixed with 70% ethanol and measured using an XCT
Research SA (Stratec Medizintechnick, Pforzheim, Germany) as
described [9].
Ultrastructural analysis
Mice were fixed with a mixture of 2% paraformaldehyde and
2.5% glutaraldehyde in 0.05 M cacodylate buffer (pH 7.4). After
decalcification, the specimens were post-fixed with osmium
tetroxide (OsO4), dehydrated, and embedded in Epon-Araldite
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lead citrate, and examined under a transmission electron
microscope (H-7100, Hitachi, Tokyo, Japan). To observe the
three-dimensional ultrastructure of osteocytes, the HCl-collage-
nase method [14] was applied. Briefly, the fixed specimens were
treated with 6N HCl at 60uC for 50 min, rinsed in 0.1 M
phosphate buffer (pH6.8), and placed in 1 mg/ml collagenase
(Sigma, Type II; 0.1 M phosphate buffer, pH 6.8) at 37uC for
12 hr. Then, they were immersed in 2% tannic acid solution for
30 min, post-fixed with 1% OsO4 in 0.05 M cacodylate buffer
(pH 7.4) at 4uC for 1 hr, dehydrated, critical point-dried in CO2
(HCP-2, Hitachi), coated with gold, and observed under a
scanning electron microscope (S-3500N, Hitachi).
Reporter assays
The 1.8-kb promoter region of the mouse Sp7 gene was
amplified from mouse genomic DNA by PCR using the following
primers, 59-AAGCTTTTCCCACTCTCTAC-39/59-CGAGCT-
Figure 1. Osteoblast differentiation in vitro. (A–D) Real-time RT-PCR analysis. A, Induction of Sp7 expression by RUNX2 in Runx2
2/2 calvarial
cells. The cells isolated using collagen gel were infected with EGFP or Runx2-EGFP expressing adenovirus (6610
6 pfu/well). RNA samples were
obtained at 6, 12, 24 and 48 hours after infection. Expression levels before infection (0) were defined as 1 and relatives levels are shown. Runx2
2/2
calvarial cells express an aberrant transcript of Runx2 at a low level. n=3. B, Sp7 expression after the infection of adenovirus carrying EGFP or Sp7.C ,
Sp7 expression after the infection of adenovirus carrying EGFP or sh-Sp7. Adenoviruses were used at 3610
6 pfu/well or 6610
6 pfu/well as indicated.
D, Alpl, Col1a1, and Bglap2 expressions were examined at 4 days or 9 days of culture after the infection. Adenoviruses were used at 3610
6 pfu/well.
The levels in cells, which were infected with EGFP-expressing adenovirus at 3610
6 pfu/well, at 4 days of culture were defined as 1, and relative levels
are shown. *p,0.05 and **p,0.001 vs. EGFP. n=4. (E) Von Kossa staining in primary osteoblasts infected with an adenovirus carrying EGFP, Sp7, sh-
Sp7,o rRunx2. Three independent experiments were performed and representative data are shown in A–E.
doi:10.1371/journal.pone.0032364.g001
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(FL) reporter vector PGL4.10Luc2 (Promega). The deletion
fragments were also subcloned into PGL4.10Luc2. 293 cells were
co-transfected with the Sp7 promoter construct, the vector
expressing Sp7, and a promoter-less Renilla Luciferase vector
which was derived from a pRL-SV40 vector (Promega) by deletion
of the SV40 promoter. ATDC5 cells were transfected with the 1.8-
kb Sp7 promoter construct and the pRL plasmid, and infected with
an adenovirus expressing EGFP or sh-Sp7. All plasmid transfec-
tions were performed using FuGENE 6 (Roche Diagnostics).
Luciferase activity was normalized to that of Renilla luciferase.
Chromatin immunoprecipitation (ChIP) assay
ChIP was performed with a Magna ChIP G Kit (Millipore,
Billerica, MA) using wild-type newborn calvarial cells. After
immunoprecipitation with anti-SP7 (Abcam, Tokyo, Japan) or
anti-IgG (Cell signaling, Tokyo, Japan) antibody and DNA
extraction, PCR was performed using the primers, 59-CCT-
CAAGCAGAGAGGACGCCA-39/59-TCCGGAGTCTTCTCC-
GCTGG-39. An aliquot of sonicated DNA before immunoprecip-
itation was amplified by PCR as a positive control.
Statistical analysis
Data are represented as the mean6S.D. Means of groups were
compared by ANOVA, and the significance of differences was
determined by post-hoc testing with Bonferroni’s method.
Results
RUNX2 induced Sp7 expression and sh-Sp7 inhibited
osteoblast differentiation, but SP7 inhibited osteoblast
differentiation at a late stage in vitro
As both RUNX2 and SP7 are required for osteoblast
differentiation and Runx2 is expressed in the mesenchymal
condensation in Sp7
2/2 mice [5], we first examined whether
RUNX2 is able to induce Sp7 expression in osteoprogenitors. The
infection of Runx2-expressing adenovirus into Runx2
2/2 calvarial
cells upregulated Sp7 expression 10 times after 6 hours and 50
times after 12–48 hours compared with that before infection
(Fig. 1A). Next, we examined the ability of SP7 in osteoblastogen-
esis in vitro. On real-time RT-PCR analysis, the introduction of
Sp7 shRNA (sh-Sp7) into primary osteoblasts reduced alkaline
phosphatase (Alpl) expression at day 4, Col1a1 expression mildly
at day 9, and Bglap2 expression at days 4 and 9, while the
introduction of Sp7 had no effect on Alpl expression, mildly
reduced Col1a1 expression at day 9, and induced Bglap2 at
day 4 but inhibited it at day 9 (Fig. 1B–D). Although the
introduction of Runx2 into primary osteoblasts apparently induced
mineralization, both Sp7 and sh-Sp7 reduced mineralization at the
higher dose (Fig. 1E). The cells were viable at a similar level after
the infection of the adenovirus expressing either EGFP, Sp7, or sh-
Sp7 at the higher dose (Fig. S1A). Further, retroviral introduction
of Sp7 also inhibited mineralization (Fig. S1B–E). These results
suggest that SP7 is required for osteoblast differentiation, but that
SP7 is not sufficient to induce osteoblast differentiation and
overexpression of Sp7 suppresses osteoblast differentiation at a late
stage in vitro.
Figure 2. Generation of Sp7 transgenic mice. (A) Diagram of the
DNA construct used to generate Sp7 transgenic mice. *Intron from SV40
containing splice donor and acceptor sites, **polyadenylation signal
from SV40. (B) Sp7 expression in long bones of wild-type mice and two
independent Sp7 transgenic lines (tg1 and tg2) at 4 weeks of age. Sp7
expression was examined by real-time RT-PCR. The level in wild-type
mice was set at 1, and relative levels are shown. **P,0.01 vs. wild-type
mice. n=4–10. (C–F) Immunohistochemistry using anti-SP7 antibody.
Trabecular bone (C, D) and cortical bone (E, F) in the femur of a wild-
type mouse (C, E) and tg2 mouse (D, F) at 1 week of age are shown.
Bars: 50 mm.
doi:10.1371/journal.pone.0032364.g002
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We generated Sp7 transgenic mice with the mouse 2.3-kb Col1a1
promoter, which specifically directs transgene expression to
immature and mature osteoblasts (Fig. 2A). We established two
lines of Sp7 transgenic mice, tg1 with low transgene expression and
tg2 with high transgene expression (Fig. 2B). SP7 expression was
examined using anti-SP7 antibody (Fig. 2C–F). The transgene
expression was detected in most osteoblasts and young osteocytes
but not in osteoclasts and chondrocytes in Sp7 transgenic mice.
The staining was not detected in other tissues except teeth, in
which odontoblasts were strongly stained (data not shown). These
results confirmed that the transgene was specifically expressed in
osteoblasts, early osteocytes, and odontoblasts by the mouse 2.3-kb
Col1a1 promoter as described previously [8], [9].
Sp7 transgenic mice show osteopenia
The two transgenic lines showed osteopenia, the severity of
which depended on the expression level of the transgene, and
fractures in the lower limbs were sometimes observed in tg2 but
not observed in tg1 by X-ray analysis (Fig. 3A and data not
shown). The osteopenic phenotype was mild at 3 days of age and
apparent after 1 week of age, but was not apparent at the newborn
stage in tg2 mice, and both the trabecular and cortical bones were
decreased with greater severity in tg2 than tg1 until 10 months of
age we examined (Fig. 3B–G, Fig. S2, and data not shown). The
direction of collagen fibers was uniform and osteocytes were
regularly located in a similar direction in the cortical bone of wild-
type mice, whereas the collagen fibers were randomly oriented
similar to those in woven bone and the osteocytes were irregularly
located and randomly oriented in tg1 and tg2 with milder
abnormalities in tg1 (Fig. 3H–J).
On transmission electron microscopy (TEM), the osteoblasts in
10-week-old wild-type mice had spread many processes into
osteoid, whereas the number of processes on osteoblasts was
reduced in Sp7 transgenic mice, probably showing the reduced
activity of osteoblasts (Fig. 3K, L). The mature osteocytes, which
reside in the lacunae, were flattened and had abundant processes
in wild-type mice, while two osteocytes were frequently observed
in one lacuna, they were irregularly shaped, and the number of
processes was less in Sp7 transgenic mice (Fig. 3M, N). In
canalicular staining, abundant canaliculi, through which the
processes of osteocytes interact with each other, regularly ran
among osteocyte lacunae and between osteocyte lacunae and bone
surface in wild-type mice (Fig. 3O), whereas the number of
canaliculi was reduced and they were irregularly oriented in Sp7
transgenic mice (Fig. 3P). On scanning electron microscopy
(SEM), preosteocytes, which are in the process of becoming
embedded into bone, and young osteocytes had abundant
processes in wild-type mice (Fig. 3Q, R), while those in Sp7
transgenic mice had a reduced number of processes (Fig. 3S, T).
Thus, overexpression of Sp7 reduced the number of processes in
both osteoblasts and osteocytes.
A pQCT analysis of 10-week-old tg2 mice revealed mineral
density to be reduced in both the trabecular and cortical bones
(Fig. 4A–C). pQCT and micro-CT analyses showed that the
cortical bone was thin and both the endosteal and periosteal
circumferences were enlarged (Fig. 4A, C and Fig. S3). A bone
histomorphometric analysis revealed the trabecular bone volume
(BV/TV) of tg2 mice to be two-thirds that of wild-type mice
(Fig. 4D). Although the osteoblast surface (Ob.S/BS) in trabecular
bone was increased in tg2 mice compared with wild-type mice,
osteoblast function was impaired as shown by the severely reduced
osteoid thickness (O.Th), mineral apposition rate (MAR), and
Figure 3. X-ray and histological analyses of Sp7 transgenic mice. (A) X-ray analysis of the femurs of a wild-type (wt), tg1, and tg2 mouse at 6
weeks of age. (B–G) Histological appearance of bone in transgenic mice. Longitudinal sections through the distal part (B–D) and diaphysis (E–G) of
femurs in a wild-type (B, E), tg1 (C, F), and tg2 (D, G) mouse at 6 weeks of age. The sections were stained with H–E. (H–J) Polarized microscopic
examination of the diaphyses of femurs from wild-type (H), tg1 (I), and tg2 (J) mice at 6 months of age. (K–T) TEM images of osteoblasts (K, L) and
osteocytes (M, N), canalicular staining of tibiae (O, P), and SEM images of preosteocytes (Q, S) and young osteocytes (R, T) of wild-type (K, M, O, Q, R)
and tg2 (L, N, P, S, T) mice at 10 weeks of age. In Q–T, bone and osteoid in cortical bone were dissolved and preosteocytes and young osteocytes just
beneath the osteoblast layer in the endosteum were observed by SEM. Bars: (B–D) 500 mm; (E–J) 50 mm; (K–N), 1 mm; (O–T), 10 mm.
doi:10.1371/journal.pone.0032364.g003
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(Oc.S/BS) in tg2 mice was similar to that in wild-type mice, and
the urinary deoxypyridinoline levels in tg2 mice were mildly
increased at 6 weeks of age and similar to that in wild-type mice at
10 weeks of age (Fig. 4D, E). These findings suggest that the
cortical bone in tg2 mice was immature, and the enlargement of
the endosteal circumference was due to the immaturity of the
cortical bone, which accelerates resorption, but not to enhanced
osteoclastogenesis as previously described in Runx2 and dominant-
negative Runx2 transgenic mice [9], [12], [13].
Figure4. pQCT and bone histomorphometric analyses and bone resorption markers. (A–C) pQCT analyses of femurs from wild-type (wt) and
tg2 mice at 10 weeks of age. A, pQCT images of the diaphyses of the femurs. Bar: 1 mm. B, The trabecular bone density in 13 equal cross-divisions of the
metaphysial parts of the femurs was measured in wild-type (open circles) and tg2 (closed circles) mice. C, Cortical bone density, cortical thickness,
endosteal circumference, and periosteal circumference of the diaphyses of the femurs were measured in wild-type (open columns) and tg2 (closed
columns) mice. n=5. (D) Bone histomorphometric analysis. Trabecular bone volume (bone volume/tissue volume, BV/TV), osteoid thickness (O.Th),
osteoblast surface (Ob.S/BS), osteoclast surface (Oc.S/BS), mineral apposition rate (MAR), and bone formation rate (BFR/BS) were compared at 10 weeks
of age. BS, bone surface. n=5. (E) Urinary deoxypyridinoline levels at 6 and 10 weeks of age. n=7–11. *P,0.05 and **P,0.01 vs. wild-type mice.
doi:10.1371/journal.pone.0032364.g004
Figure 5. BrdU uptake and real-time RT-PCR analysis. (A) The percentage of osteoblasts positive for BrdU at 2 weeks of age. n=4. (B, C) Real-
time RT-PCR analysis. B, Expression of Col1a1, Spp1, Ibsp, and Bglap2 was determined using RNA from whole bones of femurs and tibiae in wild-type
(wt), tg1, and tg2 mice at 4 weeks of age. n=5–8. *P,0.05 and **P,0.01 vs. wild-type mice. C, Expression of Dmp1, Mepe, Phex, Fgf23, Sost, Atf4,
Tnfsf11, Tnfrsf11b was determined using RNA from the osteocyte fraction of femurs and tibiae in wild-type and tg2 mice at 12 weeks of age. n=5.
**P,0.01 vs. wild-type mice. The values of the wild-type mice were defined as 1, and relative levels are shown in B and C.
doi:10.1371/journal.pone.0032364.g005
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Sp7 transgenic mice
The osteoblast proliferation was enhanced in a manner
dependent on the level of transgene expression (Fig. 5A). As
osteoblast function was impaired in Sp7 transgenic mice, we next
examined the gene expression of major bone matrix proteins. A
real-time RT-PCR analysis revealed the expression of Col1a1,
Spp1, Ibsp, and Bglap2, to be significantly reduced in tg2 mice with
the reduction in Bglap2 expression being most severe (Fig. 5B). The
expression of these genes was mildly or marginally reduced in
tg1 mice. Combined with the histological, pQCT, and bone
histomorphometric analyses (Fig. 3 and Fig. 4), these findings
indicate that overexpression of Sp7 promotes the proliferation but
inhibits the differentiation at a late stage in osteoblasts.
As the osteocytes in Sp7 transgenic mice showed morphological
changes, we also examined the expression of the genes, which are
highly expressed in osteocytes and/or mature osteoblasts, using
osteocyte-enriched fraction (Fig. 5C). The expressions of Mepe and
Sost were reduced in tg2 mice compared with wild-type mice.
However, The expressions of Dmp1, Phex, Fgf23, Atf4, Tnfsf11, and
Tnfrsf11b in tg2 mice were not significantly different from those in
wild-type mice.
SP7 and RUNX2 independently inhibit osteoblast
differentiation at a late stage
To further investigate the function of SP7 and RUNX2 in
osteoblast differentiation at a later stage, we generated Runx2/Sp7
double transgenic mice by mating tg2 mice with Runx2 transgenic
mice. The double transgenic mice showed severe osteopenia and
suffered from more severe multiple fractures than tg2 or Runx2
single transgenic mice (Fig. 6A–I). We compared the expression of
Sp7, Runx2, Col1a1, and Bglap2 among wild-type, Runx2 transgenic,
Sp7 transgenic, and Runx2/Sp7 double transgenic mice using RNA
from calvaria, in which no fractures were seen in any of the groups
(Fig. 6J). Col1a1 expression was decreased and Bglap2 expression
was markedly decreased in Runx2, Sp7, and Runx2/Sp7 double
transgenic mice compared with wild-type mice. As Sp7 expression
was not upregulated in Runx2 transgenic mice and Runx2
expression was not upregulated in Sp7 transgenic mice (Fig. 6J),
these findings indicate that SP7 and RUNX2 independently
inhibit osteoblast differentiation at a late stage.
SP7 upregulates its own promoter
The real-time RT-PCR analysis showed that the endogenous
Sp7 expression in tg2 mice was upregulated compared with that in
wild-type mice (Fig. 7A). The endogenous Sp7 expression was also
increased but mildly in primary osteoblasts from Sp7 transgenic
mice in vitro (Fig. S4). Further, the adenoviral introduction of Sp7
into wild-type osteoprogenitors induced endogenous Sp7 expres-
sion (Fig. 7B). Thus, we examined Sp7 promoter by reporter assay.
The introduction of Sp7 expression vector strongly activated the
reporter vector containing the 1.8 kb Sp7 promoter region
(Fig. 7C). In the reporter assay using the serially deleted constructs,
the proximal 170 bp was responsible for the activation (Fig. 7C).
Further, sh-Sp7 inhibited the activity of the reporter construct
containing the 1.8 kb Sp7 promoter region (Fig. 7D). ChIP assay
showed that endogenous SP7 binds to the region containing the
proximal 170 bp of Sp7 promoter (Fig. 7E). These findings
indicate that SP7 positively regulates its own promoter.
Discussion
Introduction of sh-Sp7 into primary osteoblasts inhibited
osteoblast differentiation, showing that SP7 is required for
osteoblast differentiation in vitro. However, overexpression of
Sp7 failed to induce Alpl expression and reduced Bglap2 expression
and mineralization at a late stage of osteoblast differentiation in
vitro. The induction of osteoblast differentiation by SP7 is
dependent on the cells and culture conditions in vitro [15], [16],
[17], [18], [19], [20], [21], [22], [23], [24], [25], [26]. One
possible explanation for these controversial results may be that
SP7 plays an important role in osteoblast differentiation at an early
stage but requires additional molecules to induce osteoblast
differentiation. Further, SP7 may interact with different transcrip-
tion factors at the early and late stages of osteoblast differentiation,
and SP7 may interfere with the bindings or activities of the
transcription factors, which are important for the late stage of
osteoblast differentiation.
Sp7 transgenic mice showed osteopenia due to the inhibition of
osteoblast differentiation at a late stage, which was shown by woven
bone structure inthecorticalbone,reduced mineralization,reduced
bone formation irrespective of the increased osteoblast density, and
decreased expression of bone matrix protein genes especially Bglap2.
Therefore, our experiments in vivo showed that SP7 inhibits
osteoblast differentiation at a late stage and keeps the osteoblasts in
an immature state. Although overexpression of Runx2 also inhibits
osteoblast differentiation at a late stage [9], [13], [27], SP7 and
RUNX2 do so independent of RUNX2 and SP7, respectively,
because the expression of Sp7 and Runx2 was not upregulated in
Runx2 transgenic mice and Sp7 transgenic mice, respectively.
However, RUNX2 induced Sp7 expression in Runx2
2/2 calvarial
cells, which retain the abilities to differentiate into chondrocytes and
adipocytes [28]. Further, involvement of RUNX2 in Sp7 expression
was shown in C2C12 cells, C3H10T1/2 cells, and ATDC5 cells,
which have characteristics of multipotent mesenchymal cells or
chondroprogenitors [22], [29], [30]. Thus, RUNX2 seems to
regulate Sp7 expression at an early stage of osteoblast differentiation
but not at a late stage. As RUNX2 and SP7 are essential for
osteoblast differentiation at an early stage [5], [7], [31], our findings
strengthen an idea that RUNX2 and SP7 play major roles in
osteoblast differentiation at an early stage but not a late stage.
The deletion of Sp7 in postnatal mice by CAG-CreER
completely inhibits osteoblast differentiation and severely impairs
bone formation, indicating that SP7 is essential for osteoblast
differentiation at an early stage not only in embryos but also in
postnatal mice [32]. Further, the deletion of Sp7 using 2.3 kb
Col1a1 Cre results in an increase of trabecular bone but a decrease
of cortical bone, and the deletion of Sp7 in postnatal mice by
2.3 kb Col1a1 CreERT results in a mild decrease of trabecular
Figure 6. Runx2/Sp7 double transgenic mice. (A) X-ray analysis of lower limb bones from a wild-type mouse (wt), Runx2 transgenic mouse
(Runx2), Sp7 transgenic mouse (Sp7), and Runx2/Sp7 double transgenic mouse (Runx2/Sp7) at 6 weeks of age. The double transgenic mouse (Runx2/
Sp7) suffered from multiple fractures in the femurs, tibiae, fibulae, and calcanei, and the bone is most radiolucent in non-fracture regions. (B–I) H–E
staining of sections from femurs of wild-type mice (B, F), Runx2 transgenic mice (C, G), Sp7 transgenic mice (D, H), and Runx2/Sp7 double transgenic
mice (E, I) at 6 weeks of age. Cortical bones are shown in F–I. The healing of fractures is observed in the double transgenic mouse (E). Cortical bones
are shown by brackets. Bars: (B–E), 1 mm; (F–I) 50 mm. (J) Expression of Sp7, Runx2, Col1a1, and Bgalp2 in calvaria of wild-type mice (wt), Runx2
transgenic mice (R), Sp7 transgenic mice (S), and Runx2/Sp7 double transgenic mice (R/S) at 4 weeks of age was examined by real-time RT-PCR. For
Sp7 and Runx2, both endogenous expression and expression of the transgene were detected. **P,0.01 vs. wild-type mice. n=4.
doi:10.1371/journal.pone.0032364.g006
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Sp7 knockout mice [6], [33], indicating that SP7 is still involved in
osteoblast differentiation at the stage when preosteoblasts start to
upregulate Col1a1 expression and become immature osteoblasts.
Combined with the data from the conditional Sp7 knockout mice,
our findings indicate that SP7 is required for postnatal bone
development but osteoblast differentiation is inhibited at a late
stage if the Sp7 expression is maintained at a high level at the late
stage of osteoblast differentiation.
Interestingly, the reduction in osteocyte processes was also
observed in Sp7-deleted mice with CAG-CreER [32]. Thus, either
overexpression or deletion of Sp7 reduced osteocyte processes. In
Sp7 transgenic mice, the number of osteoblast processes was also
reduced. Therefore, SP7 may be involved in the regulation of
process formation of osteoblasts and osteocytes. It is also possible
that disturbance of the differentiation of osteoblasts at a late stage
is responsible for the reduction in the number of processes in
osteoblasts and osteocytes, because the number of processes was
also reduced in osteoblasts and osteocytes in Runx2 transgenic mice
[9] (data not shown). The reduction of Mepe expression and Sost
expression in the osteocytes of Sp7 transgenic mice may reflect the
impaired mineralization and immaturity of the osteocytes,
respectively [34], [35], [36].
Osteoblast proliferation was enhanced in Sp7 transgenic mice.
The enhanced osteoblast proliferation by SP7 was also observed in
NIH3T3 fibroblasts and bone marrow stromal cells in vitro [16],
[18]. Thus, SP7 seems to have an ability to induce osteoblast
proliferation. It is also possible that the enhanced osteoblast
proliferation was due to the inhibition of osteoblast differentiation
at a late stage, which results in the accumulation of immature
osteoblasts that retain the ability to proliferate.
In conclusion, the sustained Sp7 expression at high levels during
osteoblast differentiation inhibited osteoblast differentiation at a
late stage. Thus, the stage-dependent regulation of Sp7 mRNA
expression and protein activity during osteoblast differentiation is
essential for bone formation. The auto-regulatory loop of SP7 may
play an important role in maintaining a sufficient level of SP7 at
an early stage of osteoblast differentiation.
Supporting Information
Figure S1 (A) Quantification of formazan’s incorporation into
primary osteoblasts. The cells were infected with adenovirus
(6610
6 pfu/well) carrying EGFP, Sp7 or sh-Sp7 at confluence, and
MTT assay was performed after 4 days of culture in osteogenic
media. Data is presented as mean 6 S.D. of absorbance values
measured on 4 wells. (B–E) SP7 inhibits mineralization. Primary
osteoblast cultures infected with retrovirus carrying EGFP (B, D)
or Sp7-EGFP (C, E). B and C, Dark field images showing cells
expressing the respective transgene. Von Kossa staining (D, E) was
performed 10 days after infection.
(TIF)
Figure S2 Histological analysis. H–E staining of sections of
tibiae from wild-type (A, B, E, F, I, J, M, N) and tg2 (C, D, G, H,
K, L, O, P) mice at 1 week (A–D), 2 weeks (E–H), 4 weeks (I–L)
and 10 months (M–P) of age. Boxed regions in A, C, E, G, I, K,
Figure 7. Positive regulation of Sp7 promoter by SP7. (A, B) Real-time RT-PCR analysis. A, Endogenous Sp7 expression in wild-type and tg2
mice at 18 weeks of age. RNA was prepared from tibiae and femurs, in which hematopoietic cells were flushed out. *P,0.05 vs. wild-type mice. n=4–
5. B, Osteoprogenitors isolated from wild-type calvaria using collagen gel were infected with adenovirus expressing EGFP or Sp7 at 6610
6 pfu/well,
and endogenous Sp7 expression was examined. **p,0.001 vs. EGFP-expressing cells. The level in wild-type mice or EGFP-expressing cells was set at
1, and relative values are shown. (C, D) Reporter assays using the Sp7 promoter. C, The reporter activity using the 1.8-kb Sp7 promoter-luciferase (Luc)
construct and the deletion constructs. Reporter assays were performed using 293T cells with (closed columns) or without (open columns) the Sp7
expression vector. The lines in the schematic diagram of the Sp7 promoter indicate putative SP1-binding sites. D, The reporter activity using the 1.8-
kb Sp7 promoter in ATDC5 cells infected with adenovirus expressing EGFP or sh-Sp7 at 6610
6 pfu/well. *p,0.05 and **p,0.001 vs. control. (E) ChIP
assay. DNA before immunoprecipitation (input) and after immunoprecipitation with anti-SP7 antibody or anti-IgG antibody was amplified by PCR
using primers that amplify the region containing the proximal 170 bp of Sp7 promoter.
doi:10.1371/journal.pone.0032364.g007
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bars: (A,C,E,G,I,K,M,O) 200 mm, (B,D,F,H,J,L,N,P) 50 mm.
(TIF)
Figure S3 Micro-CT analysis. (A–B) Micro-CT images of
cortical bones in femora of wild-type (A) and tg2 (B) mice at 15
weeks of age. (C) Cortical bone ratio (bone volume/total volume).
(D) Medullary ratio (medullary volume/total volume). (E)
Endosteal circumference. (F) Periosteal circumference. Parameters
were measured on cortical bone of the femoral diaphysis.
*P,0.05, **P,0.005 vs. wild-type mice. n=3.
(TIF)
Figure S4 Real time RT-PCR analysis. (A) Exogenous and
endogenous Sp7 expression. (B) Endogenous Sp7 expression.
Primary osteoblasts from wild-type and Sp7 transgenic mice were
plated on 24-well plates at a density of 3610
5 cells/well and RNA
was extracted 2 days later. n=6 .**P,0.01 vs. wild-type primary
osteoblasts.
(TIF)
Procedures S1 MTT assay.
(DOC)
Procedures S2 Retrovirus infection.
(DOC)
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